Literature DB >> 24489528

Precursor-to-product ratios reflect biochemical phenotype in congenital adrenal hyperplasia.

Rebecca A Hicks1, Jennifer K Yee1, Catherine S Mao1, Steve Graham2, Martin Kharrazi2, Fred Lorey2, W P Lee1.   

Abstract

Precursor-to-product ratios in steroid hormone metabolism may accurately reflect enzymatic activity and production of metabolites relative to their disappearance. The purpose of this study was to explore the use of direct precursor-to-product steroid ratios to discriminate between infants with congenital adrenal hyperplasia (CAH) due to 21- α -hydroxylase deficiency and infants with no disorder, thus characterizing the biochemical phenotype in CAH. Deidentified dried blood spot samples from confirmed CAH cases identified by newborn screen (CAH-positive, N = 8) and from cases with no disorder (CAH-negative, N = 10) were obtained from the California State Newborn Screening Program. Samples (∼6.25 mm circular spots) underwent methanol and water extraction (9:1 ratio). Deuterated steroids served as isotope internal standards. 17-α-hydroxyprogesterone (17-OHP), 11-deoxycortisol (S), androstenedione (A4) and cortisol (F) concentrations were determined by liquid chromatography-tandem mass spectrometry (LC-MS/MS), and the 17-OHP/S, 17-OHP/A4, and S/F ratios were calculated. The mean 17-OHP and A4 concentrations in samples from CAH cases were significantly increased when compared to cases with no disorder (p = 0.003 for both). 17-OHP/S and 17-OHP/A4 ratios were also significantly elevated in CAH cases (p = 0.007 and p < 0.001, respectively). In contrast, S and F concentrations and the S/F ratio were similar between the two groups. In CAH, the elevated 17-OHP/S ratio is a biomarker of diminished 21-α-hydroxylase activity, and the elevated 17-OHP/A4 ratio is a biomarker of adrenal androgen excess via increased 17,20-lyase activity. The similar S/F ratio indicates that the rate of production via 11-β-hydroxylase and disappearance of F is maintained in CAH.

Entities:  

Keywords:  Congenital adrenal hyperplasia; Newborn screening; Precursor-to-product ratios; Steroid profiling

Year:  2014        PMID: 24489528      PMCID: PMC3904458          DOI: 10.1007/s11306-013-0558-1

Source DB:  PubMed          Journal:  Metabolomics        ISSN: 1573-3882            Impact factor:   4.290


  18 in total

Review 1.  Consensus statement on 21-hydroxylase deficiency from the Lawson Wilkins Pediatric Endocrine Society and the European Society for Paediatric Endocrinology.

Authors: 
Journal:  J Clin Endocrinol Metab       Date:  2002-09       Impact factor: 5.958

2.  Adrenal steroidogenesis in very low birth weight preterm infants.

Authors:  R V Hingre; S J Gross; K S Hingre; D M Mayes; R A Richman
Journal:  J Clin Endocrinol Metab       Date:  1994-02       Impact factor: 5.958

3.  An automated method on analysis of blood steroids using liquid chromatography tandem mass spectrometry: application to population screening for congenital adrenal hyperplasia in newborns.

Authors:  Kuldeep Dhillon; Thomson Ho; Patti Rich; Dadong Xu; Fred Lorey; Jianwen She; Ajit Bhandal
Journal:  Clin Chim Acta       Date:  2011-07-23       Impact factor: 3.786

4.  Cortisol in dried blood screening specimens from newborns with raised 17-hydroxyprogesterone and congenital adrenal hyperplasia.

Authors:  M L Mitchell; R J Hermos
Journal:  Clin Endocrinol (Oxf)       Date:  1998-06       Impact factor: 3.478

5.  Newborn screening for congenital adrenal hyperplasia: additional steroid profile using liquid chromatography-tandem mass spectrometry.

Authors:  N Janzen; M Peter; S Sander; U Steuerwald; M Terhardt; U Holtkamp; J Sander
Journal:  J Clin Endocrinol Metab       Date:  2007-04-24       Impact factor: 5.958

Review 6.  Neonatal screening for congenital adrenal hyperplasia.

Authors:  Perrin C White
Journal:  Nat Rev Endocrinol       Date:  2009-09       Impact factor: 43.330

7.  17-Hydroxyprogesterone in premature infants as a marker of intrauterine stress.

Authors:  Jörg Ersch; Ernst Beinder; Thomas Stallmach; Hans Ulrich Bucher; Toni Torresani
Journal:  J Perinat Med       Date:  2008       Impact factor: 1.901

8.  Reduction of the false-positive rate in newborn screening by implementation of MS/MS-based second-tier tests: the Mayo Clinic experience (2004-2007).

Authors:  D Matern; S Tortorelli; D Oglesbee; D Gavrilov; P Rinaldo
Journal:  J Inherit Metab Dis       Date:  2007-07-23       Impact factor: 4.982

9.  False positive rate in newborn screening for congenital adrenal hyperplasia (CAH)-ether extraction reveals two distinct reasons for elevated 17alpha-hydroxyprogesterone (17-OHP) values.

Authors:  Ralph Fingerhut
Journal:  Steroids       Date:  2009-03-09       Impact factor: 2.668

10.  Steroid profiling by tandem mass spectrometry improves the positive predictive value of newborn screening for congenital adrenal hyperplasia.

Authors:  Carla Z Minutti; Jean M Lacey; Mark J Magera; Si Houn Hahn; Mark McCann; Andreas Schulze; David Cheillan; Claude Dorche; Donald H Chace; James F Lymp; Donald Zimmerman; Piero Rinaldo; Dietrich Matern
Journal:  J Clin Endocrinol Metab       Date:  2004-08       Impact factor: 5.958

View more
  4 in total

Review 1.  The hunt for a selective 17,20 lyase inhibitor; learning lessons from nature.

Authors:  Ian M Bird; David H Abbott
Journal:  J Steroid Biochem Mol Biol       Date:  2016-05-03       Impact factor: 4.292

2.  Utility of a precursor-to-product ratio in the evaluation of presumptive positives in newborn screening of congenital adrenal hyperplasia.

Authors:  P Y Tieh; J K Yee; R A Hicks; C S Mao; W-Np Lee
Journal:  J Perinatol       Date:  2016-12-08       Impact factor: 2.521

3.  A Multiclassifier System to Identify and Subtype Congenital Adrenal Hyperplasia Based on Circulating Steroid Hormones.

Authors:  Lei Ye; Zhiyun Zhao; Huixia Ren; Wencui Wang; Wenzhong Zhou; Sichang Zheng; Rulai Han; Jie Zhang; Haorong Li; Zhihan Wan; Chao Tang; Shouyue Sun; Weiqing Wang; Guang Ning
Journal:  J Clin Endocrinol Metab       Date:  2022-07-14       Impact factor: 6.134

4.  Evaluation of a Two-Tier Screening Pathway for Congenital Adrenal Hyperplasia in the New South Wales Newborn Screening Programme.

Authors:  Fei Lai; Shubha Srinivasan; Veronica Wiley
Journal:  Int J Neonatal Screen       Date:  2020-08-12
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.